On Nov 06, major Wall Street analysts update their ratings for $Bruker Corp (BRKR.US)$, with price targets ranging from $69 to $80.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $90 to $80.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $78.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $80 to $75.
Barclays analyst Luke Sergott maintains with a buy rating, and adjusts the target price from $75 to $69.
Wells Fargo analyst Brandon Couillard maintains with a buy rating, and maintains the target price at $75.
Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:
Bruker experienced continued softness in the China market and within the biopharma sector during the quarter, according to an analyst.
The company faced a challenging earnings report amidst a difficult macroeconomic climate. Adjustments to forecasts are being made in light of revised fiscal 2024 targets. Despite the adjustments, there is optimism that the company's strong positioning in multi-omics and materials sciences will enable it to capitalize on the anticipated demand resurgence in the biopharma sector and Chinese market.
Bruker's Q3 outcomes fell short of expectations, and the company has reduced its projections for organic sales growth for fiscal 2024, attributing this adjustment to a slower rebound in China and emerging biopharma sectors. According to the analyst, this recalibration of guidance was not caused by a significant downturn in Q3 markets, but rather by previously optimistic forecasts. Despite the revised guidance, the company's management remains optimistic about prospects for 2025.
The company reported a miss for Q3, but the observed trends in BSI Bookings and the updated guidance could improve the outlook as the company heads into Q4.
The positive aspect of the revised guidance for the second half of the year is that it sets the stage for a recalibration of expectations for 2025, potentially lifting a burden for investors.
Here are the latest investment ratings and price targets for $Bruker Corp (BRKR.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月6日，多家华尔街大行更新了$布鲁克 (BRKR.US)$的评级，目标价介于69美元至80美元。
摩根大通分析师Rachel Vatnsdal维持买入评级，并将目标价从90美元下调至80美元。
美银证券分析师Michael Ryskin维持买入评级，目标价78美元。
花旗分析师Patrick B Donnelly维持买入评级，并将目标价从80美元下调至75美元。
巴克莱银行分析师Luke Sergott维持买入评级，并将目标价从75美元下调至69美元。
富国集团分析师Brandon Couillard维持买入评级，维持目标价75美元。
此外，综合报道，$布鲁克 (BRKR.US)$近期主要分析师观点如下：
据一位分析师称，Bruker在本季度的中国市场和生物制药板块持续疲软。
在艰难的宏观经济环境下，公司面临着具有挑战性的盈利报告。根据修订后的2024财年目标，正在对预测进行调整。尽管进行了调整，但公司在多组学和材料科学领域的强势定位使其能够在预期需求复苏的生物制药板块和中国市场上获利，因而仍然抱有乐观态度。
Bruker的第三季度业绩未达预期，公司已调低其对2024财年有机销售增长的预期，将这一调整归因于中国和新兴生物制药板块复苏较慢。根据分析师的说法，这一指导方针的调整并非是由于第三季度市场的明显下滑，而是由于先前乐观的预测。尽管有了修订后的指引，公司管理层仍对2025年的前景持乐观态度。
公司在第三季度报告中出现了偏差，但BSI预订趋势和更新后的指引可能会使公司迈入第四季度时看到改善的前景。
对于年后半段修订后的指引的积极方面在于为2025年的预期重新校准铺平了道路，有望减轻投资者的负担。
以下为今日6位分析师对$布鲁克 (BRKR.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
